drugset / Trial / NCT00586092
A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors
NaSingle-groupOpen-label
Summary
The primary objective of this study is to determine the recommended Phase II dose for the combination of ABT-510 plus bevacizumab in patients with advanced solid tumors and to evaluate dose limiting toxicities and non-dose limiting toxicities of this combination. The secondary objectives are to collect preliminary data on the effect of the combination of ABT-510 plus bevacizumab versus each agent individually on dermal wound angiogenesis in a skin biopsy and to collect preliminary data on the clinical activity of this combination (tumor response rate, progression-free survival, rate of stable disease \> 6 months).
Timeline
- Start
- 2005-09
- Primary completion
- 2013-02
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABT-510 | Peptide | 25 mg | Subcutaneous |
| Subject | ABT-510 | Peptide | 50 mg | Subcutaneous |
| Subject | ABT-510 | Peptide | 100 mg | Subcutaneous |
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |